About Collagen alpha-1(XXVI) chain
Collagen alpha-1(XXVI) chain (COL26A1) is a protein
from Homo sapiens identified by UniProt accession
Q96A83, 441 residues long.
MolForge cross-references it against 0 known binders and
62 disease associations.
Target properties
| Protein name | Collagen alpha-1(XXVI) chain |
| UniProt accession | Q96A83 |
| Gene | COL26A1 |
| Organism | Homo sapiens |
| Length | 441 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (62)
Diseases linked to this target (Open Targets).
- cortical thickness · score 0.40
- neuroimaging measurement · score 0.38
- brain measurement · score 0.36
- cortical surface area measurement · score 0.32
- response to antidepressant · score 0.31
- intraocular pressure measurement · score 0.30
- mental or behavioural disorder · score 0.27
- hemoglobin measurement · score 0.26
- breast adenocarcinoma · score 0.26
- lung adenocarcinoma · score 0.18
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q96A83-F1 | alphafold | PREDICTED | 59.65 | — |
Amino-acid sequence (441 residues)
MKLALLLPWA CCCLCGSALA TGFLYPFSAA ALQQHGYPEP GAGSPGSGYA SRRHWCHHTV TRTVSCQVQN GSETVVQRVY QSCRWPGPCA NLVSYRTLIR PTYRVSYRTV TVLEWRCCPG FTGSNCDEEC MNCTRLSDMS ERLTTLEAKV LLLEAAERPS SPDNDLPAPE STPPTWNEDF LPDAIPLAHP VPRQRRPTGP AGPPGQTGPP GPAGPPGSKG DRGQTGEKGP AGPPGLLGPP GPRGLPGEMG RPGPPGPPGP AGNPGPSPNS PQGALYSLQP PTDKDNGDSR LASAIVDTVL AGVPGPRGPP GPPGPPGPRG PPGPPGTPGS QGLAGERGTV GPSGEPGVKG EEGEKAATAE GEGVQQLREA LKILAERVLI LEHMIGIHDP LASPEGGSGQ DAALRANLKM KRGGAQPDGV LAALLGPDPG QKSVDQASSR K
Explore Collagen alpha-1(XXVI) chain with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets